Enlivex Adopts Bitcoin Treasury Reserve Strategy
Enlivex Therapeutics (Nasdaq: ENLV) announced its Board of Directors has approved the purchase of up to $1 million of Bitcoin as part of its cash management strategy. The clinical-stage macrophage reprogramming immunotherapy company views Bitcoin as a strong and diversifying treasury reserve asset, citing growing demand, increased acceptance as a medium of exchange, recent Bitcoin ETF approvals, and institutional investor support. The company believes Bitcoin can serve as a potential store of value and inflation hedge against standard currencies.
Enlivex Therapeutics (Nasdaq: ENLV) ha annunciato che il proprio Consiglio di Amministrazione ha approvato l'acquisto di fino a 1 milione di dollari in Bitcoin come parte della propria strategia di gestione della liquidità. La società, specializzata in terapie immunologiche di riprogrammazione dei macrofagi in fase clinica, considera il Bitcoin un solido e diversificato asset di riserva di tesoreria, citando l'aumento della domanda, una maggiore accettazione come mezzo di scambio, le recenti approvazioni di ETF su Bitcoin e il supporto degli investitori istituzionali. La società crede che il Bitcoin possa fungere da potenziale riserva di valore e da protezione contro l'inflazione rispetto alle valute standard.
Enlivex Therapeutics (Nasdaq: ENLV) anunció que su Junta Directiva ha aprobado la compra de hasta 1 millón de dólares en Bitcoin como parte de su estrategia de gestión de efectivo. La compañía, que se encuentra en una etapa clínica de reprogramación de macrófagos mediante inmunoterapia, considera el Bitcoin como un activo de reserva tesorera sólido y diversificado, citando la creciente demanda, una mayor aceptación como medio de intercambio, las recientes aprobaciones de ETF de Bitcoin y el apoyo de inversores institucionales. La compañía cree que el Bitcoin puede servir como una potencial reserva de valor y un protector contra la inflación frente a las monedas estándar.
Enlivex Therapeutics (Nasdaq: ENLV)는 이사회가 현금 관리 전략의 일환으로 최대 100만 달러의 비트코인을 구매하기로 승인했다고 발표했습니다. 임상 단계의 대식세포 재프로그래밍 면역 요법 회사인 이 회사는 비트코인을 강력하고 다양화된 재무 자산으로 보고하며, 증가하는 수요, 교환 매체로서의 수용 증가, 최근 비트코인 ETF 승인 및 기관 투자자의 지원을 이유로 들고 있습니다. 이 회사는 비트코인이 잠재적인 가치 저장 수단 및 표준 통화에 대한 인플레이션 헤지로 작용할 수 있다고 믿고 있습니다.
Enlivex Therapeutics (Nasdaq: ENLV) a annoncé que son Conseil d'Administration a approuvé l'achat de jusqu'à 1 million de dollars en Bitcoin dans le cadre de sa stratégie de gestion de trésorerie. L'entreprise, spécialisée dans l'immunothérapie de reprogrammation des macrophages en phase clinique, considère le Bitcoin comme un actif de réserve de trésorerie solide et diversifié, faisant état d'une demande croissante, d'une acceptation accrue comme moyen d'échange, des récentes approbations d'ETF Bitcoin et du soutien des investisseurs institutionnels. L'entreprise estime que le Bitcoin peut servir de réserve de valeur potentielle et de couverture contre l'inflation par rapport aux monnaies standard.
Enlivex Therapeutics (Nasdaq: ENLV) gab bekannt, dass der Vorstand den Kauf von bis zu 1 Million Dollar in Bitcoin als Teil seiner Cash-Management-Strategie genehmigt hat. Das Unternehmen, das sich in der klinischen Phase für die Reprogrammierung von Makrophagen durch Immuntherapie befindet, betrachtet Bitcoin als ein starkes und diversifiziertes Treasury-Reserve-Asset und nennt wachsende Nachfrage, erhöhte Akzeptanz als Tauschmittel, die jüngsten Genehmigungen von Bitcoin-ETFs und die Unterstützung institutioneller Investoren. Das Unternehmen glaubt, dass Bitcoin als potenzielle Wertaufbewahrung und Inflationsschutz gegenüber Standardwährungen dienen kann.
- Strategic diversification of treasury reserves with up to $1 million Bitcoin allocation
- Exposure to cryptocurrency market volatility risks
- Allocation of cash reserves to highly speculative asset class
Insights
This
- Bitcoin's high volatility could impact financial stability
- Regulatory uncertainties in the crypto space
- Potential distraction from core business operations
For a clinical-stage biotech company with typically high cash burn rates, this strategy introduces additional market risk to their treasury. While Bitcoin ETF approvals have improved institutional acceptance, the company's small size makes it particularly vulnerable to cryptocurrency market swings.
Nes-Ziona, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company’s Board of Directors approved the purchase of up to
“As demand for Bitcoin has grown, together with its rising acceptance as a recognized medium of exchange, we believe that Bitcoin will serve the Company as a strong and diversifying treasury reserve asset,” said Oren Hershkovitz, CEO of Enlivex. “With the recent approvals of Bitcoin ETFs and growing support from institutional investors, we believe that Bitcoin can provide the Company with a potential functional store of value and an inflation hedge to standard currencies.”
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit https://enlivex.com/.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com
INVESTOR RELATIONS CONTACT
Dave Gentry, CEO
RedChip Companies Inc.
1-407-644-4256
ENLV@redchip.com
FAQ
How much Bitcoin will Enlivex Therapeutics (ENLV) purchase?
Why is Enlivex Therapeutics (ENLV) investing in Bitcoin?
When did Enlivex Therapeutics (ENLV) announce its Bitcoin strategy?
